AI-generated from publicly available materials.Fundly.ai, a Mumbai-based startup, has raised $4.9 million in funding to enhance its B2B pharmaceutical platform, reflecting a growing trend in the digitization of India's drug supply chain.
The funding round, which includes $4 million in equity and $0.9 million in venture debt, was led by Accel and Multiply Ventures, alongside participation from angel investors such as Rajeev Ahuja. Established in 2021, Fundly.ai has evolved from a supply-chain finance provider into a comprehensive operating system for the pharmaceutical sector. Its platform offers a digital interface for retail pharmacies and distributors to streamline procurement, payments, and access to working capital, thereby addressing inefficiencies in the traditional supply chain.
Fundly.ai has demonstrated impressive financial growth, with revenues soaring from ₹53 million in FY2024 to ₹274 million in FY2025. The platform currently connects over 4,100 retail and distribution partners across more than 24 cities, facilitating substantial disbursements. However, it remains EBITDA-negative, a common scenario for startups focused on rapid growth rather than immediate profitability. As a privately held entity, it is not publicly traded, which limits market valuation insights.
Despite its growth trajectory, Fundly.ai faces inherent risks associated with its credit-dependent model, particularly concerning payment cycles and potential defaults. The competitive landscape of B2B SaaS and fintech will require the company to sustain healthy margins while expanding its operations. Moving forward, the startup aims to leverage its new funding to standardize its digital infrastructure and broaden its geographic reach, with key performance indicators focusing on loan quality and capital efficiency.